eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer

• Published in: Science signaling Vol. 17; no. 826; p. eadh4475
• Main Authors: Treekitkarnmongkol, Warapen, Solis, Luisa M, Sankaran, Deivendran, Gagea, Mihai, Singh, Pankaj K, Mistry, Ragini, Nguyen, Tristian, Kai, Kazuharu, Liu, Jiajun, Sasai, Kaori, Jitsumori, Yoshimi, Liu, Jianwen, Nagao, Norio, Stossi, Fabio, Mancini, Michael A, Wistuba, Ignacio I, Thompson, Alastair M, Lee, Jonathan M, Cadiñanos, Juan, Wong, Kwong-Kwok, Abbott, Catherine M, Sahin, Aysegul A, Liu, Suyu, Katayama, Hiroshi, Sen, Subrata
• Format: Journal Article
• Language: English
• Published: United States 05.03.2024
• Subjects: Animals; Aurora Kinase A - genetics; Aurora Kinase A - metabolism; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; F-Box-WD Repeat-Containing Protein 7 - genetics; Female; Glycogen Synthase Kinase 3 beta; Humans; Mammary Neoplasms, Animal - genetics; Mammary Neoplasms, Animal - metabolism; Mammary Neoplasms, Animal - pathology; Mice; Peptide Elongation Factor 1 - genetics; Peptide Elongation Factor 1 - metabolism; PTEN Phosphohydrolase - genetics; PTEN Phosphohydrolase - metabolism
• ISSN: 1937-9145
• DOI: 10.1126/scisignal.adh4475

The translation elongation factor eEF1A promotes protein synthesis. Its methylation by METTL13 increases its activity, supporting tumor growth. However, in some cancers, a high abundance of eEF1A isoforms is associated with a good prognosis. Here, we found that eEF1A2 exhibited oncogenic or tumor-suppressor functions depending on its interaction with METTL13 or the phosphatase PTEN, respectively. METTL13 and PTEN competed for interaction with eEF1A2 in the same structural domain. PTEN-bound eEF1A2 promoted the ubiquitination and degradation of the mitosis-promoting Aurora kinase A in the S and G2 phases of the cell cycle. eEF1A2 bridged the interactions between the SKP1-CUL1-FBXW7 (SCF) ubiquitin ligase complex, the kinase GSK3β, and Aurora-A, thereby facilitating the phosphorylation of Aurora-A in a degron site that was recognized by FBXW7. Genetic ablation of or in mice resulted in a greater abundance of Aurora-A and increased cell cycling in mammary tumors, which was corroborated in breast cancer tissues from patients. Reactivating this pathway using fimepinostat, which relieves inhibitory signaling directed at PTEN and increases expression, combined with inhibiting Aurora-A with alisertib, suppressed breast cancer cell proliferation in culture and tumor growth in vivo. The findings demonstrate a therapeutically exploitable, tumor-suppressive role for eEF1A2 in breast cancer.